Subsequent analysis of the impact of oral UA dosing on immune cells in the subcutaneous B16F10 tumor model demonstrated an increase in the number of CD8+ T cells in both the tumor and spleen Figure 7D; Figure S11A, Supporting Information), substantiating that UA promotes CD8+ T cell persistence. Here, CD8A is linked to neoplasm.